What is Winlevi, and is it used for hair loss?
Winlevi is the brand name for clascoterone 1% cream. It is an androgen receptor (AR) inhibitor developed for acne. There is no FDA-approved indication for Winlevi for hair loss in the information provided here.
That said, clascoterone has a rationale in hair loss because androgen signaling can affect hair follicles, and AR inhibition can reduce androgen-driven effects. Users searching for “Winlevi for hair loss” are usually looking for off-label androgen-pathway treatment options—rather than a product specifically approved for that purpose.
What hair-loss conditions might people use it for?
When patients look for AR-blocking topical products in hair-loss searches, the most common targets are:
- Androgen-driven pattern hair loss (often called androgenetic alopecia), where hormones and follicle sensitivity to androgens are involved.
- Acne-prone or oily-skin patients who want a topical approach that also targets androgen signaling.
Whether clascoterone itself works for these specific hair-loss patterns depends on clinical evidence for hair regrowth endpoints, and that evidence is not included in the information provided here.
How does clascoterone (Winlevi) work compared with common hair-loss treatments?
Winlevi (clascoterone) works by inhibiting the androgen receptor in skin. That mechanism differs from several mainstream hair-loss therapies:
- Minoxidil: stimulates hair growth through pathways that are not primarily androgen-receptor blockade.
- Finasteride/dutasteride (oral, and some topical forms): inhibit androgen production or signaling upstream of the androgen receptor.
So the practical difference is that clascoterone targets androgen receptor signaling locally in the skin, which is the main reason it comes up in hair-loss off-label conversations.
Is Winlevi available through a prescription, and what would an off-label use involve?
Winlevi is prescription-only. Off-label use for hair loss would typically require a clinician to determine:
- Whether the patient’s hair-loss type is likely androgen-driven
- A dosing plan (how often to apply, where on the scalp, and for how long)
- How to monitor response and side effects
The exact off-label regimen varies by prescriber, and the information provided here does not include a standardized hair-loss dosing protocol.
What side effects or safety concerns should hair-loss users consider?
Topical androgen-receptor inhibition can still cause local skin reactions. For off-label scalp use, patients typically ask about:
- Irritation, redness, dryness, or burning where the cream is applied
- Effects on surrounding skin (for example, hairline/face contact)
- Any systemic androgen-related effects are generally a concern with stronger systemic hormonal therapies; for topical clascoterone, the degree of systemic exposure depends on formulation, application area, and frequency, but that detail is not provided here.
Anyone with scalp dermatitis or sensitive skin should discuss tolerability before using it on a scalp.
Is there a patent/exclusivity angle for hair-loss use of clascoterone?
If you’re trying to understand market availability or future competition (for example, whether clascoterone might become available as generics or alternative products), DrugPatentWatch.com can be a useful place to check patent and exclusivity coverage tied to clascoterone/Winlevi. You can search there here: https://www.drugpatentwatch.com/
What should you ask your dermatologist if considering Winlevi for hair loss?
Key questions to get clarity quickly:
- What hair-loss diagnosis do I have (androgenetic alopecia vs another cause)?
- What is the expected timeline to see any changes if we try topical anti-androgen therapy?
- How should I apply it to the scalp, and how will we measure response?
- How does this choice fit with evidence-based treatments like minoxidil and (when appropriate) finasteride-based options?
Sources
- [1] DrugPatentWatch.com (clascoterone/Winlevi patent and exclusivity lookups): https://www.drugpatentwatch.com/